Literature DB >> 16849386

One year outcome of intensive care patients with decompensated alcoholic liver disease.

I J Mackle1, D G Swann, B Cook.   

Abstract

BACKGROUND: We aimed to examine the outcome of patients with decompensated alcoholic liver disease (ALD) admitted to a general intensive care unit (ICU).
METHODS: Retrospective observational cohort study of intensive care admissions over a 3 yr period was conducted. The study was set in an ICU in a UK university hospital with a tertiary liver referral unit. One hundred and ten admissions, involving 107 patients, with decompensated ALD were included. Intensive care, hospital, and 6 and 12 months mortality were recorded along with the outcome in diagnostic and organ system support subgroups. Intensive care, hospital, 6 month and 12 month mortality rates were 58, 71, 78 and 81%.
RESULTS: Hospital mortality in the sepsis/multiorgan failure group was 88%. Sixty-nine per cent of patients who were ventilated but required no other organ support survived to hospital discharge. However, the requirement for any other organ support, or a raised creatinine (>120 micromol litre(-1)) in the first 24 h, reduced the hospital survival to <15%. In those patients requiring acute renal replacement therapy, the hospital mortality was 94%.
CONCLUSION: Decompensated ALD requiring intensive care admission is associated with a high hospital mortality and consideration should be given to the futility of escalating organ support measures, particularly when renal replacement therapy is required.

Entities:  

Mesh:

Year:  2006        PMID: 16849386     DOI: 10.1093/bja/ael177

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  9 in total

Review 1.  Bacterial infections in end-stage liver disease: current challenges and future directions.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Florence Wong; K Rajender Reddy; Patrick S Kamath
Journal:  Gut       Date:  2012-06-03       Impact factor: 23.059

2.  The use of VV-ECMO in patients with drug dependencies.

Authors:  George Stoyle; Peter Fawcett; Ignacio Malagon
Journal:  J Artif Organs       Date:  2018-02-20       Impact factor: 1.731

3.  Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis.

Authors:  Brianna E Vaa; Sumeet K Asrani; Winston Dunn; Patrick S Kamath; Vijay H Shah
Journal:  Mayo Clin Proc       Date:  2011-01       Impact factor: 7.616

4.  Prevalence and outcome of cirrhosis patients admitted to UK intensive care: a comparison against dialysis-dependent chronic renal failure patients.

Authors:  Alastair J O'Brien; Cathy A Welch; Mervyn Singer; David A Harrison
Journal:  Intensive Care Med       Date:  2012-03-29       Impact factor: 17.440

5.  Factors that predict short-term intensive care unit mortality in patients with cirrhosis.

Authors:  Ranjeeta Bahirwani; Marwan Ghabril; Kimberly A Forde; Hemant Chatrath; Karen M Wolf; Lindsay Uribe; K Rajender Reddy; Barry Fuchs; Naga Chalasani
Journal:  Clin Gastroenterol Hepatol       Date:  2013-04-16       Impact factor: 11.382

Review 6.  Acute and chronic ethanol consumption differentially impact pathways limiting hepatic protein synthesis.

Authors:  Anne M Karinch; Jonathan H Martin; Thomas C Vary
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-03-11       Impact factor: 4.310

7.  Alcoholic liver disease on the intensive care unit - Outcomes and prognostication.

Authors:  James I Beck; Anca Staicu; Simon M Everett; Phil Jackson
Journal:  J Intensive Care Soc       Date:  2016-08-03

8.  Long-Term Mortality and Hospital Resource Use in ICU Patients With Alcohol-Related Liver Disease.

Authors:  Nazir I Lone; Robert Lee; Timothy S Walsh
Journal:  Crit Care Med       Date:  2019-01       Impact factor: 7.598

9.  Long-term outcome of patients with liver cirrhosis admitted to a general intensive care unit.

Authors:  Alex Warren; Charlotte R Soulsby; Alex Puxty; Joseph Campbell; Martin Shaw; Tara Quasim; John Kinsella; Joanne McPeake
Journal:  Ann Intensive Care       Date:  2017-04-04       Impact factor: 6.925

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.